First patients enter global Phase 3 test in metastatic pancreatic cancer Daraxonrasib is being tested alone and with chemotherapy in untreated metastatic PDAC. Why it matters: the study tracks survival and disease progression.

#RVMD Revolution Medicines Begins Treating Patients in Phase 3 RASolute 303 Trial Evaluating Daraxonrasib as First Line Treatment for Patients with Metastatic Pancreatic Cancer 

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Slides After Q4 Results RVMD fell ~12% on Mar 29, 2026 after Q4 commentary; cash of ~$650M as of Dec 31, 2025 implies runway into mid-2027, making H2 2026 and Q1 2027 readouts critical.

Revolution Medicines Slides After Q4 Results: RVMD fell ~12% on Mar 29, 2026 after Q4 commentary; cash of ~$650M as of Dec 31, 2025 implies runway into mid-2027, making H2 2026 and Q1 2027 readouts critical. 👈 Read full analysis #RevolutionMedicines #RVMD #Q4Results #StockMarket #Pharmaceuticals

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#UAMY, #U, #MSTR, #FIGR, #RVMD

#OptionFlow #OptionsTrading #Trading

#RVMD stock pops amid acquisition rumors with Merck and Biotech companies.

NEWS: ( NASDAQ: #RVMD ) Why Revolution Medicines Stock Surged by 11% Today

💼 $MRK in talks to acquire $RVMD cancer biotech | Deal valued $28-32B | +16% afterhours | Watch oncology M&A heat as pharma consolidation accelerates

📈 #RVMD stock jumps after acquisition buzz — biotech shares surged on reports big pharma is eyeing a takeover, boosting investor optimism.

#RVMD stock price pops amid acquisition rumors, market value expected to rise to $32 billion.

Today’s most trending tickers with positive sentiment (last 24h):

#AAPL: 25
#OPEN: 18
#SPY: 13
#INTC: 11
#GOOGL: 10
#CETX: 9
#GOOG: 9
#AMZN: 9
#TSLA: 9
#QQQ: 8
#RKT: 8
#NXXT: 8
#ASTS: 7
#NVDA: 7
#RVMD: 6
#JPM: 6
#PRFX: 6
#JD: 5

📢 Stocks Trending NOW: #APLD #LMT #INTC #BX #ABBV #RTX #RVMD #NOC #LUCY #STZ

Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has initiated RASolute 304, a Phase 3 clinical trial of daraxonrasib as adjuvant treatment for patients

#RVMD Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted a

#RVMD Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress Revolution Medicines (Nasdaq: RVMD) reported Q2 2025 financial results and corporate updates, highlighting significant progress in its oncology pipeline. The company's lead drug daraxonrasib received FDA Breakthrough Therapy Designation for PDAC treatment, with Phase 3 trial RASolute 302 expected to complete enrollment this year. A major financial milestone includes securing a $2 billion flexible funding agreement with Royalty Pharma.The company reported Q2 2025 financial results with a net loss of $247.8 million (vs $133.2 million in Q2 2024), R&D expenses of $224.1 million, and G&A expenses of $40.6 million. Cash position stands at $2.1 billion, including $250 million from Royalty Pharma. Full-year 2025 projected GAAP net loss is estimated between $1.03-1.09 billion.Multiple clinical programs are advancing, including elironrasib's FDA Breakthrough Therapy Designation for NSCLC treatment and promising developments with zoldonrasib for KRAS G12D mutations.

#RVMD Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor Revolution Medicines (NASDAQ:RVMD) announced the publication of a peer-reviewed paper in Science detailing the discovery and development of zoldonrasib, their RAS(ON) G12D-selective covalent inhibitor. The drug targets RAS G12D mutations, which are present in 92% of pancreatic cancer, 50% of colorectal cancer, and 30% of non-small cell lung cancer cases.The paper highlights zoldonrasib's novel tri-complex inhibitor mechanism, which creates a neomorphic protein-protein interface between cyclophilin A and activated RAS to selectively target RAS(ON) G12D proteins. Preclinical data showed significant tumor regression in multiple tumor types with KRAS G12D mutations.The drug is currently being evaluated in clinical trials, including the RMC-9805-001 Phase 1 study for patients with advanced solid tumors harboring KRAS G12D mutations.

#RVMD Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib Revolution Medicines (NASDAQ:RVMD) announced that the FDA has granted Breakthrough Therapy Designation to its drug elironrasib for treating adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who have received prior chemotherapy and immunotherapy but haven't been treated with a KRAS G12C inhibitor.The designation is based on promising results from the Phase 1 RMC-6291-001 clinical trial, which demonstrated competitive antitumor activity, differentiated safety profile, and compelling objective response rate and progression-free survival. Elironrasib targets the RAS(ON) form of RAS G12C variant, present in approximately 12% of NSCLC cases.This breakthrough designation aims to expedite development and review of the drug, addressing a significant unmet medical need in NSCLC, which accounts for 80%-85% of all lung cancers.

#RVMD Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Taps Iambic's AI Platform in $25M Deal to Accelerate Cancer Drug Discovery Revolutionary AI-powered collaboration combines Iambic's NeuralPLexer with Revolution's oncology expertise to tackle challenging drug targets. Learn breakthrough details.

#RVMD Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Launches Major Cancer Trial: 3 RAS Inhibitors Combined with Novel PD-1 Therapy New clinical collaboration explores breakthrough cancer treatment combining three RAS inhibitors with PD-1/VEGF antibody for lung and GI cancers. See trial details.

#RVMD Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations Revolution Medicines (NASDAQ: RVMD) has received FDA Breakthrough Therapy Designation for daraxonrasib, targeting previously treated metastatic pancreatic cancer with KRAS G12 mutations. The designation is based on promising Phase 1 trial data and aims to expedite development and review of this potential treatment. The company is currently conducting RASolute 302, a Phase 3 registrational study expected to complete enrollment in 2025, with results anticipated in 2026. The study focuses on patients with pancreatic ductal adenocarcinoma (PDAC), where over 90% of cases carry RAS mutations, with approximately 85% specifically having KRAS G12 mutations. The trial's dual primary endpoints include progression-free survival and overall survival in the core patient population.

#RVMD Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer with KRAS G12 Mutations

www.stocktitan.net/news/RVMD/revolution-med...

Revolutionary Cancer Drug Enters Phase 3 Trial, Targeting 30% of Lung Cancer Patients Without Current Options Novel RAS inhibitor daraxonrasib begins pivotal trial for lung cancer patients with limited treatment options. 420-patient study targets 30% of cases. See trial details.

#RVMD Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress Revolution Medicines (RVMD) reported Q1 2025 financial results and clinical progress. The company reported a net loss of $213.4M, up from $116M in Q1 2024, with $2.1B in cash expected to fund operations into 2H 2027. Key clinical highlights include strong enrollment in Phase 3 trials for daraxonrasib, particularly RASolute 302 for pancreatic cancer. The company shared promising data for its RAS(ON) inhibitors: zoldonrasib showed 61% ORR in NSCLC, elironrasib demonstrated 56% ORR with 9.9 months median PFS, and various combination therapies displayed encouraging results. Notable combinations include daraxonrasib with pembrolizumab achieving 86% ORR in first-line NSCLC. The company strengthened its commercial capabilities by appointing Anthony Mancini as chief global commercialization officer.

#RVMD Revolution Medicines Reports First Quarter 2025 Financial Results and Update on Corporate Progress

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting Revolution Medicines (RVMD) has presented initial clinical data for zoldonrasib (RMC-9805), their RAS(ON) G12D-selective inhibitor, in treating KRAS G12D mutant non-small cell lung cancer (NSCLC) patients. The Phase 1 study results were presented at the 2025 AACR Annual Meeting.Key findings from the study with 90 solid tumor patients treated with 1200 mg once daily dose showed:61% objective response rate in 18 efficacy-evaluable NSCLC patients89% disease control rate98% mean dose intensity with no dose limiting toxicitiesAcceptable safety profile with mostly Grade 1 or 2 adverse eventsCommon treatment-related adverse events included nausea (39%), diarrhea (24%), vomiting (18%), and rash (12%). Only 2% of patients experienced Grade 3 events, which resolved after dose interruption.

#RVMD Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting Revolution Medicines (RVMD) announced 11 presentations at the upcoming 2025 AACR Annual Meeting in Chicago (April 25-30, 2025). The highlight will be the first clinical data presentation of zoldonrasib, their RAS(ON) G12D-selective inhibitor, in non-small cell lung cancer patients during a late-breaking oral session.Key presentations include preliminary safety and antitumor activity data of zoldonrasib in KRAS G12D NSCLC patients, the discovery of RMC-5127 (a RAS(ON) G12V-selective inhibitor), and clinical activity data of daraxonrasib in RAS mutant NSCLC. Additional presentations will cover resistance mechanisms, combination therapies, and immune response in various cancer types including pancreatic and colorectal cancers.

#RVMD Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress Revolution Medicines (RVMD) reported its Q4 and full year 2024 financial results, highlighting progress in its RAS-focused cancer drug development programs. The company ended Q4 2024 with a net loss of $194.6M, compared to $161.5M in Q4 2023, while full-year 2024 net loss was $600.1M.Key developments include advancing Phase 3 trials for daraxonrasib in pancreatic and lung cancers. The company expects to complete enrollment in the RASolute 302 trial for metastatic pancreatic cancer in 2025, with data readout in 2026. Two additional registrational trials for pancreatic cancer are planned for H2 2025.Financially, RVMD strengthened its position through an $823M public equity offering in December 2024, ending the year with $2.3B in cash. The company projects 2025 GAAP net loss between $840M-$900M and expects current funds to support operations into H2 2027.

#RVMD Revolution Medicines Reports Fourth Quarter and Full Year 2024 Financial Results and Update on Corporate Progress

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Secures Massive $750M Public Offering with Upsized Share Sale | RVMD Stock News Revolution Medicines prices substantial $750M offering at $46/share, including common stock and pre-funded warrants, backed by major financial institutions.

#RVMD Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants

#news #investing #stocks

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

#RVMD Revolution Medicines Announces Commencement of Public Offering of Common Stock

#offering #stocks #investing

www.stocktitan.net/news/RVMD/revolution-med...

Revolution Medicines' Cancer Drug Shows 36% Response Rate in Pancreatic Cancer Trial | RVMD Stock News Clinical trial reveals promising results for RMC-6236 with 36% response rate in pancreatic cancer and strong efficacy in lung cancer. Phase 3 trials planned for 2025.

#RVMD Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio

#news #investing #stocks

www.stocktitan.net/news/RVMD/revolution-med...